Retargeting of adenoviral gene delivery via Herceptin-PEG-adenovirus conjugates to breast cancer cells

Journal of Controlled Release

Volumn 123, Issue 2, 2007, Pages 164-171

  Jung, Yukyung ^a   Park, Hyo Jin ^a   Kim, Pyung Hwan ^a,b   Lee, Jaewon ^a   Hyung, Woochan ^a   Yang, Jaemoon ^a   Ko, Hyunju ^c   Sohn, Joo Hyuk ^b   Kim, Joo Hang ^a,b   Huh, Yong Min ^a,c   Yun, Chae Ok ^a,b   Haam, Seungjoo ^a  

^a Yonsei University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

Author keywords

Adenovirus; Gene therapy; Herceptin; PEG; Targeting

Indexed keywords

CELL DEATH; CELL GROWTH; IMMUNOLOGY; POLYETHYLENE GLYCOLS; TUMORS; VIRUSES;

ADENOVIRAL GENE; GENE THERAPY; HERCEPTIN; PEGYLATED ADENOVIRUS (PEG-ADV);

GENES;

GREEN FLUORESCENT PROTEIN; INTERLEUKIN 6; MACROGOL; TRASTUZUMAB;

ADENOVIRUS; ARTICLE; BREAST CANCER; CANCER CELL; CELL LINE; CONTROLLED STUDY; GENE TARGETING; HUMAN; HUMAN CELL; INNATE IMMUNITY; MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CHROMATOGRAPHY, LIQUID; FEASIBILITY STUDIES; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GENES, REPORTER; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; INTERLEUKIN-6; LIGHT; MACROPHAGES; MICE; MICROSCOPY, ELECTRON, TRANSMISSION; POLYETHYLENE GLYCOLS; RECEPTOR, ERBB-2; SCATTERING, RADIATION; TRANSDUCTION, GENETIC;

EID: 35348835660     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2007.08.002     Document Type: Article

References (33)

1. Kootstra N.A., and Verma I.M. Gene therapy with viral vectors. Annu. Rev. Pharmacol. Toxicol. 43 1 (2003) 413-439
2. Wilson J.M. Adenovirus-mediated gene transfer to liver. Adv. Drug Deliv. Rev. 17 3 (1995) 303-307
3. Mizuguchi H., and Hayakawa T. Targeted adenovirus vectors. Hum. Gene Ther. 15 (2004) 1034-1044
4. Yang Y., Li Q., Ertl H.C.J., and Wilson J.M. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol. 69 4 (1995) 2004-2015
5. Majhen D., and Ambriović-Ristov A. Adenoviral vectors-how to use in cancer gene therapy?. Virus Res. 119 2 (2006) 121-133
6. Goosney D.L., and Nemerow G.R. Adenovirus infection: taking the back roads to viral entry. Curr. Biol. 13 3 (2003) R99-R100
7. Tripathy S.K., Black H.B., Goldwasser E., and Leiden J.M. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus. Nat. Med. 2 5 (1996) 545-550
8. Yang Y., Jooss K.U., Su Q., Ertl H.C., and Wilson J.M. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther. 3 (1996) 137-144
9. O'riordan C.R., Lachapelle A., Delgado C., Parkes V., Wadsworth S.C., Smith A.E., and Francis G.E. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum. Gene Ther. 10 8 (1999) 1349-1358
10. Croyle M.A., Chirmule N., Zhang Y., and Wilson J.M. "Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J. Virol. 75 10 (2001) 4792-4801
11. Croyle M.A., Callahan S.M., Auricchio A., Schumer G., Linse K.D., Wilson J.M., Brunner L.J., and Kobinger G.P. PEGylation of a vesicular stomatitis virus G pseudotyped lentivirus vector prevents inactivation in serum. J. Virol. 78 2 (2004) 912-921
12. Croyle M.A., Le H.T., Linse K.D., Cerullo V., Toietta G., Beaudet A., and Pastore L. PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile. Gene Ther. 12 7 (2005) 579-587
13. Eto Y., Gao J., Sekiguchi F., Kurachi S., Katayama K., Mizuguchi H., Hayakawa T., Tsutsumi Y., Mayumi T., and Nakagawa S. Neutralizing antibody evasion ability of adenovirus vector induced by the bioconjugation of methoxypolyethylene glycol succinimidyl propionate (MPEG-SPA). Biol. Pharm. Bull. 27 6 (2004) 936-938
14. Croyle M.A., Yu Q., and Wilson J.M. Development of a rapid method for the PEGylation of adenoviruses with enhanced transduction and improved stability under harsh storage conditions. Hum. Gene Ther. 11 12 (2000) 1713-1722
15. Croyle M.A., Chirmule N., Zhang Y., and Wilson J.M. PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. Hum. Gene Ther. 13 15 (2002) 1887-1900
16. Mok H., Palmer D.J., Ng P., and Barry M.A. Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol. Ther. 11 1 (2005) 66-79
17. Romanczuk H., Galer C.E., Zabner J., Barsomian G., Wadsworth S.C., and O'riordan C.R. Modification of an adenoviral vector with biologically selected peptides: a novel strategy for gene delivery to cells of choice. Hum. Gene Ther. 10 16 (1999) 2615-2626
18. Ogawara K., Rots M.G., Kok R.J., Moorlag H.E., Loenen A.V., Meijer D.K.F., Haisma H.J., and Molema G. A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo. Hum. Gene Ther. 15 5 (2004) 433-443
19. Lanciotti J., Song A., Doukas J., Sosnowski B., Pierce G., Gregory R., Wadsworth S., and O'Riordan C. Targeting adenoviral vectors using heterofunctional polyethylene glycol FGF2 conjugates. Hum. Gene Ther. 8 1 (2003) 99-107
20. Maeda M., Kida S., Hojo K., Eto Y., Gaob J., Kurachi S., Sekiguchi F., Mizuguchi H., Hayakawa T., Mayumi T., Nakagawa S., and Kawasaki K. Design and synthesis of a peptide-PEG transporter tool for carrying adenovirus vector into cells. Bioorg. Med. Chem. Lett. 15 3 (2005) 621-624
21. Eto Y., Gao J., Sekiguchi F., Kurachi S., Katayama K., Maeda M., Kawasaki K., Mizuguchi H., Hayakawa T., Tsutsumi Y., Mayumi T., and Nakagawa S. PEGylated adenovirus vectors containing RGD peptides on the tip of PEG show high transduction efficiency and antibody evasion ability. J. Gene Med. 7 5 (2005) 604-612
22. Oh I.K., Mok H., and Park T.G. Folate immobilized and PEGylated adenovirus for retargeting to tumor cells. Bioconjug. Chem. 17 3 (2006) 721-727
23. Chiu S., Ueno N.T., and Lee R.J. Tumor-targeted gene delivery via anti-HER2 antibody (trastuzumab, HerceptinÒ) conjugated polyethylenimine. J. Control. Release 97 2 (2004) 357-369
24. Burstein H.J. The Distinctive nature of HER2-positive breast cancers. N. Engl. J. Med. 353 (2005) 1652-1654
25. Mume E., Orlova A., Larsson B., Nilsson A., Nilsson F.Y., Sjöberg S., and Tolmachev V. Evaluation of ((4-hydroxyphenyl)ethyl)maleimide for site-specific radiobromination of anti-HER2 affibody. Bioconjug. Chem. 16 6 (2005) 1547-1555
26. Nobs L., Buchegger F., Gurny R., and Allémann E. Biodegradable nanoparticles for direct or two-step tumor immunotargeting. Bioconjug. Chem. 17 1 (2006) 139-145
27. HER2 immunoliposomes for cancer therapy. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 1327-1331
28. Mandler R., Wu C., Sausville E.A., Roettinger A.J., Newman D.J., Ho D.K., King C.R., Yang D., Lippman M.E., Landolfi N.F., Dadachova E., Brechbiel M.W., and Waldmann T.A. Immunoconjugates of geldanamycin and anti-HER2 monoclonal antibodies: antiproliferative activity on human breast carcinoma cell lines. J. Natl. Cancer Inst. 92 19 (2000) 1573-1580
29. HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 4285-4289
30. Vogel C., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L., Slamon D.J., Murphy M., Novotny W.F., Burchmore M., Shak S., and Stewart S.J. First-line, single-agent herceptinÒ (trastuzumab) in metastatic breast cancer: a preliminary report. Eur. J. Cancer 37 (2001) S25-S29
31. Maizel J.V., White D.O., and Scharff M.D. The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology 36 (1968) 115-125
32. Hall S., Davis S., and Mann S. Cocondensation of organosilica hybrid shells on nanoparticle templates: a direction synthetic route to functionalized core-shell colloids. Langmuir 16 (2000) 1454-1456
33. Chen H., Jiang J., Huang Y., Deng T., Li J., Shen G., and Yu R. An electrochemical impedance immunosensor with signal amplification based on Au-colloid labeled antibody complex. Sens. Actuators, B, Chem. 117 (2006) 211-218